Endovesical instillation of Cidofovir in the treatment of BK polyomavirus hemorrhagic cystitis after allogeneic hematopoietic cell transplantation

IF 3.2 4区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Adrien Voisot , François Triffaux , Isabelle Roland , Cecile Meex , Nancy Detrembleur , Fréderic Baron , Evelyne Willems , Waltregny David , Yves Beguin , Sophie Servais
{"title":"Endovesical instillation of Cidofovir in the treatment of BK polyomavirus hemorrhagic cystitis after allogeneic hematopoietic cell transplantation","authors":"Adrien Voisot ,&nbsp;François Triffaux ,&nbsp;Isabelle Roland ,&nbsp;Cecile Meex ,&nbsp;Nancy Detrembleur ,&nbsp;Fréderic Baron ,&nbsp;Evelyne Willems ,&nbsp;Waltregny David ,&nbsp;Yves Beguin ,&nbsp;Sophie Servais","doi":"10.1016/j.retram.2022.103366","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p><span><span>Hemorrhagic cystitis (HC) with </span>BK polyomavirus (BKPyV) is a common complication after allogeneic hematopoietic </span>cell transplantation (alloHCT) that may lead to severe discomfort for the patient and significant morbidity (urinary obstruction, increased transfusion requirements and prolonged hospitalization). So far, there is no clear consensus on how to manage this complication.</p></div><div><h3>Patients and methods</h3><p>Here, we report a single-center case series of 9 patients (4 children and 5 adults) treated with cidofovir endovesical (EV) instillation(s) for BKPyV-HC after alloHCT. EV Cidofovir was administered at a dose of 5 mg/kg, for 1 to 3 instillations (with a minimum delay between 2 successive doses of 5 days).</p></div><div><h3>Results</h3><p>Eight out of the 9 treated patients with EV Cidofovir achieved a complete resolution of HC after 1–3 instillation(s), without recurrence of symptomatic infection within the next 3 months. Only 1 adult patient did not improve after treatment and developed severe morbidity (emphysematous cystitis).</p></div><div><h3>Conclusion</h3><p>Although this single-center case series of EV cidofovir for BKPyV HC after alloHCT shows encouraging results, only large prospective studies will definitively establish the effectiveness of this therapy.</p></div>","PeriodicalId":54260,"journal":{"name":"Current Research in Translational Medicine","volume":"71 1","pages":"Article 103366"},"PeriodicalIF":3.2000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Research in Translational Medicine","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2452318622000344","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 1

Abstract

Background

Hemorrhagic cystitis (HC) with BK polyomavirus (BKPyV) is a common complication after allogeneic hematopoietic cell transplantation (alloHCT) that may lead to severe discomfort for the patient and significant morbidity (urinary obstruction, increased transfusion requirements and prolonged hospitalization). So far, there is no clear consensus on how to manage this complication.

Patients and methods

Here, we report a single-center case series of 9 patients (4 children and 5 adults) treated with cidofovir endovesical (EV) instillation(s) for BKPyV-HC after alloHCT. EV Cidofovir was administered at a dose of 5 mg/kg, for 1 to 3 instillations (with a minimum delay between 2 successive doses of 5 days).

Results

Eight out of the 9 treated patients with EV Cidofovir achieved a complete resolution of HC after 1–3 instillation(s), without recurrence of symptomatic infection within the next 3 months. Only 1 adult patient did not improve after treatment and developed severe morbidity (emphysematous cystitis).

Conclusion

Although this single-center case series of EV cidofovir for BKPyV HC after alloHCT shows encouraging results, only large prospective studies will definitively establish the effectiveness of this therapy.

异基因造血细胞移植后膀胱内滴注西多福韦治疗BK多瘤病毒出血性膀胱炎
背景BK多瘤病毒(BKPyV)引起的出血性膀胱炎(HC)是异基因造血细胞移植(alloHCT)后的常见并发症,可能导致患者严重不适和显著的发病率(尿路梗阻、输血需求增加和住院时间延长)。到目前为止,对于如何处理这种复杂情况还没有达成明确的共识。患者和方法在此,我们报告了一个由9名患者(4名儿童和5名成人)组成的单中心病例系列,这些患者在同种异体HCT后接受西多福韦膀胱内滴注治疗BKPyV HC。EV Cidovovir以5mg/kg的剂量给药,滴注1-3次(连续两次给药之间的最小延迟为5天)。结果在9名接受EV Cidofovir治疗的患者中,有8名在滴注1-3次后HC完全缓解,在接下来的3个月内没有症状感染复发。只有1名成年患者在治疗后没有好转,并出现了严重的发病率(肺气肿性膀胱炎)。结论尽管EV西多福韦治疗同种异体HCT后BKPyV HC的单中心病例系列显示出令人鼓舞的结果,但只有大型前瞻性研究才能确定该疗法的有效性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Current Research in Translational Medicine
Current Research in Translational Medicine Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology
CiteScore
7.00
自引率
4.90%
发文量
51
审稿时长
45 days
期刊介绍: Current Research in Translational Medicine is a peer-reviewed journal, publishing worldwide clinical and basic research in the field of hematology, immunology, infectiology, hematopoietic cell transplantation, and cellular and gene therapy. The journal considers for publication English-language editorials, original articles, reviews, and short reports including case-reports. Contributions are intended to draw attention to experimental medicine and translational research. Current Research in Translational Medicine periodically publishes thematic issues and is indexed in all major international databases (2017 Impact Factor is 1.9). Core areas covered in Current Research in Translational Medicine are: Hematology, Immunology, Infectiology, Hematopoietic, Cell Transplantation, Cellular and Gene Therapy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信